Market accessOfficial
AIFA: Italian public pharmaceutical spending hits €13.42bn in first half of 2026
🇮🇹 AIFA · Thu 19 Nov 2026
AIFA's definitive monitoring report puts January–June public drug spending at 19.07% of the provisional national health fund, with retail spending above its ceiling in several regions.
Italy's public pharmaceutical expenditure (retail dispensing through the convenzionata channel, direct purchases and oxygen) totalled €13,417.6 million in the first six months of 2026, according to AIFA's definitive monitoring report. That equals 19.07% of the provisional 2026 national health fund (FSN) figure, which the Ministry of Health communicated by note no. 12829 of 27 July 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.
More Market access
All →
SÚKL publishes draft Czech reimbursement list effective 20 November 2026
🇨🇿 SÚKL · Fri 20 Nov 2026
SÚKL launches expanded ASTERx system for pricing and reimbursement proceedings, retires Verso
🇨🇿 SÚKL · Fri 20 Nov 2026
AIFA publishes outcomes of November Scientific and Economic Committee meeting
🇮🇹 AIFA · Fri 20 Nov 2026
Nova Biomedical starts field safety action on StatStrip ketone test strips over QC failures
🇳🇱 IGJ · Thu 19 Nov 2026
Getinge recalls CARDIOSAVE balloon pumps in Canada over reversed-polarity capacitors
🇨🇦 Health Canada · Thu 19 Nov 2026
ICU Medical recalls Portex endotracheal tubes in Canada over plasticizer variability in resin
🇨🇦 Health Canada · Thu 19 Nov 2026